{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:57:54Z","timestamp":1768571874125,"version":"3.49.0"},"posted":{"date-parts":[[2025,6,9]]},"group-title":"Pharmacology and Therapeutics","reference-count":46,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,6,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Variations in clinical pharmacokinetics and genetics, and polypharmacy affect attainment of target drug concentrations in HIV-TB co-infected patients. However, scarcity of analytical methods hinders drug concentration measurement for therapeutic drug monitoring in this doubly vulnerable population in low-and-middle income countries. This study aimed to develop and validate an LC-MS method for simultaneous determination of dolutegravir, nevirapine, efavirenz, rifampicin, isoniazid and rifapentine concentrations in plasma. ThermoScientific LCQ ion trap operated by Xcalibur\u2122 software was used. Analyte extraction from plasma was achieved by protein precipitation using 100% acetonitrile. Injection volume was 30\u00b5l for dolutegravir, efavirenz and nevirapine and 10\u00b5l for rifampicin and rifapentine. Analyte separation was achieved on Waters Atlantis dC18 column by 400\u00b5l flow rate of mobile phase under gradient elution. Transitions used were; dolutegravir (419.13\u2192277.00), efavirenz (315.03\u2192316.00), nevirapine (266.16\u2192267.10), rifampicin (822.41\u2192790.20), rifapentine (876.45\u2192845.50), dolutegravir-d4 (423.13\u2192280.10) and rifampicin-d4 (826.41\u2192795.20). Calibration curves were constructed using quadratic regression with dynamic weighting of x = y, 1\/x and 1\/x\n                  <jats:sup>2<\/jats:sup>\n                  and accepted at r\n                  <jats:sup>2<\/jats:sup>\n                  \u2265 0.95 for all validation parameters. Method linearity and recovery ranged from 0.25\u00b5g\/ml to 10.00\u00b5g\/ml and 86.12% to 109.89% respectively for all analytes. Intra-and inter-day accuracy ranged from 88.73% to 109.67% and 93.38% to 104.30% respectively for all analytes. Both intra-and inter-day precision ranged from 2.47 RSD to 12.39 RSD and 5.34 RSD to 16.83 RSD respectively for all analytes. The method was selective and specific with no significant ghost peak identified in blank samples at expected retention times of dolutegravir, efavirenz, nevirapine, rifampicin and rifapentine. An LC-MS method for simultaneous determination of dolutegravir, efavirenz, nevirapine, rifampicin and rifapentine in human plasma was developed and validated. The method could be useful to the Uganda Ministry of Health for therapeutic drug monitoring in HIV-TB patients in health facilities in the country.\n                <\/jats:p>","DOI":"10.1101\/2025.06.08.25329229","type":"posted-content","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T17:15:25Z","timestamp":1749489325000},"source":"Crossref","is-referenced-by-count":0,"title":["A High-Performance Liquid Chromatography-Mass Spectrometry method for simultaneous determination of dolutegravir, nevirapine, efavirenz, rifampicin and rifapentine concentrations in human plasma"],"prefix":"10.64898","author":[{"given":"Denis","family":"Omali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moses","family":"Ocan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hindum","family":"Lanyero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1211-7762","authenticated-orcid":false,"given":"Martin Kamilo","family":"Angwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Castelnuovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Buzibye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025061108100758000_2025.06.08.25329229v1.1","unstructured":"World Health Organisation. Global tuberculosis report 2024 2024 [Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024."},{"issue":"9","key":"2025061108100758000_2025.06.08.25329229v1.2","first-page":"e0003600","volume":"4","year":"2024","journal-title":"Correlates of HIV treatment adherence self-efficacy among adolescents and young adults living with HIV in southwestern Uganda"},{"issue":"06","key":"2025061108100758000_2025.06.08.25329229v1.3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3855\/jidc.13603","article-title":"Senga Sembuche Mulugu, Catherine Gale Gitige, Elia John Mmbaga. Rate and predictors of HIV virological failure among adults on first-line antiretroviral treatment in Dar Es Salaam, Tanzania","volume":"15","year":"2021","journal-title":"The Journal of Infection in Developing Countries"},{"key":"2025061108100758000_2025.06.08.25329229v1.4","first-page":"747","volume":"58","year":"2019","journal-title":"A systematic review on the effect of HIV infection on the pharmacokinetics of first-line tuberculosis drugs"},{"key":"2025061108100758000_2025.06.08.25329229v1.5","doi-asserted-by":"crossref","unstructured":"Pooranagangadevi N , Padmapriyadarsini CJFiTD. Treatment of tuberculosis and the drug interactions associated with HIV-TB co-infection treatment. 2022;3:834013.","DOI":"10.3389\/fitd.2022.834013"},{"issue":"1","key":"2025061108100758000_2025.06.08.25329229v1.6","first-page":"1956","volume":"12","year":"2023","journal-title":"Building clinical pharmacology laboratory capacity in low-and middle-income countries: Experience from Uganda"},{"key":"2025061108100758000_2025.06.08.25329229v1.7","unstructured":"Health UMo. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations: World Health Organization; 2016."},{"key":"2025061108100758000_2025.06.08.25329229v1.8","doi-asserted-by":"crossref","unstructured":"Sundell J , Bienvenu E , \u00c4bel\u00f6 A , Ashton MJJoAC. Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV. 2021.","DOI":"10.1093\/jac\/dkab258"},{"key":"2025061108100758000_2025.06.08.25329229v1.9","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00046-21"},{"key":"2025061108100758000_2025.06.08.25329229v1.10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy179"},{"issue":"11","key":"2025061108100758000_2025.06.08.25329229v1.11","doi-asserted-by":"crossref","first-page":"e0043023","DOI":"10.1128\/aac.00430-23","article-title":"Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard-versus high-dose rifampicin","volume":"67","year":"2023","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"3","key":"2025061108100758000_2025.06.08.25329229v1.12","first-page":"e910","volume":"76","year":"2023","journal-title":"Decreased dolutegravir and efavirenz concentrations with preserved virological suppression in patients with tuberculosis and human immunodeficiency virus receiving high-dose rifampicin"},{"key":"2025061108100758000_2025.06.08.25329229v1.13","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02174-18"},{"issue":"11","key":"2025061108100758000_2025.06.08.25329229v1.14","first-page":"e00431","volume":"67","year":"2023","journal-title":"Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin"},{"issue":"1","key":"2025061108100758000_2025.06.08.25329229v1.15","first-page":"23","article-title":"Toxicology","volume":"17","year":"2021","journal-title":"Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems"},{"key":"2025061108100758000_2025.06.08.25329229v1.16","doi-asserted-by":"crossref","unstructured":"Adaway JE , Keevil BGJJoCB . Therapeutic drug monitoring and LC\u2013MS\/MS. 2012;883:33-49.","DOI":"10.1016\/j.jchromb.2011.09.041"},{"key":"2025061108100758000_2025.06.08.25329229v1.17","doi-asserted-by":"crossref","unstructured":"Shipkova M , Svinarov DJCb. LC\u2013MS\/MS as a tool for TDM services: where are we? 2016;49(13-14):1009-23.","DOI":"10.1016\/j.clinbiochem.2016.05.001"},{"key":"2025061108100758000_2025.06.08.25329229v1.18","unstructured":"Malinga TH. LC-MS\/MS method development and validation for simultaneous quantification of first-line HIV drugs and second-line TB drugs in rat plasma 2018."},{"issue":"1-2","key":"2025061108100758000_2025.06.08.25329229v1.19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jchromb.2005.12.016","article-title":"Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography. Journal of chromatography B","volume":"831","year":"2006","journal-title":"Analytical technologies in the biomedical and life sciences"},{"key":"2025061108100758000_2025.06.08.25329229v1.20","first-page":"1","article-title":"Lab AitC","volume":"34","year":"2024","journal-title":"Rapid and sensitive liquid chromatographic\u2013tandem mass spectrometric methods for the quantitation of dolutegravir in human plasma and breast milk"},{"key":"2025061108100758000_2025.06.08.25329229v1.21","first-page":"1","volume":"7","year":"2016","journal-title":"A LC\u2013MS\/MS method with column coupling technique for simultaneous estimation of lamivudine, zidovudine, and nevirapine in human plasma"},{"issue":"2","key":"2025061108100758000_2025.06.08.25329229v1.22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jchromb.2004.03.002","article-title":"High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. Journal of chromatography B","volume":"805","year":"2004","journal-title":"Analytical technologies in the biomedical and life sciences"},{"key":"2025061108100758000_2025.06.08.25329229v1.23","doi-asserted-by":"crossref","unstructured":"Rigo-Bonnin R , Garc\u00eda-Tejada L , Mas-Bosch V , Imaz A , Tiraboschi JM , Sc\u00e9vola S , et al. Development and validation of equilibrium dialysis UHPLC-MS\/MS measurement procedures for total and unbound concentrations of bictegravir, dolutegravir, darunavir and doravirine in human plasma. Application to patients with HIV. 2024;552:117678.","DOI":"10.1016\/j.cca.2023.117678"},{"key":"2025061108100758000_2025.06.08.25329229v1.24","doi-asserted-by":"crossref","unstructured":"Sudha P , Dang RJIJoPE , Research. The Fast and Simple LC-MS\/MS Method for Determination of Rifampicin in the Human Blood Plasma. 2024;58.","DOI":"10.5530\/ijper.58.2s.60"},{"key":"2025061108100758000_2025.06.08.25329229v1.25","first-page":"55","article-title":"Fletcher CVJJop, analysis b","volume":"104","year":"2015","journal-title":"Determination of the rifamycin antibiotics rifabutin, rifampin, rifapentine and their major metabolites in human plasma via simultaneous extraction coupled with LC\/MS\/MS"},{"key":"2025061108100758000_2025.06.08.25329229v1.26","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000443"},{"issue":"5","key":"2025061108100758000_2025.06.08.25329229v1.27","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/QAI.0000000000001447","article-title":"Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates","volume":"75","year":"2017","journal-title":"Journal of acquired immune deficiency syndromes"},{"key":"2025061108100758000_2025.06.08.25329229v1.28","doi-asserted-by":"publisher","DOI":"10.1177\/2042098616667704"},{"key":"2025061108100758000_2025.06.08.25329229v1.29","unstructured":"Administration FaD . Bioanalytical Method Validation\u2014Guidance for Industry. U.S. Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation. 2018."},{"key":"2025061108100758000_2025.06.08.25329229v1.30","unstructured":"Health USDo, Human Services CfDE, Research, Center for Veterinary M. Bioanalytical Method Validation: Guid-ance for Industry. https:\/\/www.fdagov\/downloads\/Drugs\/Guidance\/ucm070107pdf2018."},{"issue":"288","key":"2025061108100758000_2025.06.08.25329229v1.31","first-page":"2","article-title":"Bioanalytical method validation and its pharmaceutical application-a review","volume":"5","year":"2014","journal-title":"Pharm Anal Acta"},{"key":"2025061108100758000_2025.06.08.25329229v1.32","doi-asserted-by":"crossref","unstructured":"Atkins PWR , R George de Paula , Julio Wormald , Mark. Physical chemistry for the life sciences: Oxford University Press; 2023.","DOI":"10.1093\/hesc\/9780198830108.001.0001"},{"key":"2025061108100758000_2025.06.08.25329229v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2011.07.041"},{"issue":"5","key":"2025061108100758000_2025.06.08.25329229v1.34","first-page":"432","article-title":"Xu HJJoCS","volume":"59","year":"2021","journal-title":"Rapid and Sensitive LC-MS\/MS Method for Simultaneous Determination of Three First-Line Oral Antituberculosis Drug in Plasma"},{"issue":"2","key":"2025061108100758000_2025.06.08.25329229v1.35","first-page":"207","article-title":"Simultaneous Determination of Blood Concentrations of Five Antiretrovirals in Human Plasma by Ultra High Performance Liquid Chromatography-tandem Mass Spectormetry Method","volume":"43","year":"2024","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"1","key":"2025061108100758000_2025.06.08.25329229v1.36","first-page":"17","volume":"40","year":"2018","journal-title":"Systematic review of salivary versus blood concentrations of antituberculosis drugs and their potential for salivary therapeutic drug monitoring"},{"issue":"4","key":"2025061108100758000_2025.06.08.25329229v1.37","first-page":"477","article-title":"Development","volume":"46","year":"2024","journal-title":"Validation, and Clinical Application of an Ultra\u2013High-Performance Liquid Chromatography Coupled With Tandem Mass Spectrometry Method for the Determination of 10 Antituberculosis Drugs in Human Serum"},{"issue":"1","key":"2025061108100758000_2025.06.08.25329229v1.38","doi-asserted-by":"crossref","first-page":"104807","DOI":"10.1016\/j.idnow.2023.104807","article-title":"Optimizing the use of current antituberculosis drugs to overcome drug resistance in Mycobacterium tuberculosis","volume":"54","year":"2024","journal-title":"Infectious diseases now"},{"issue":"1","key":"2025061108100758000_2025.06.08.25329229v1.39","first-page":"81","volume":"23","year":"2024","journal-title":"Detection of multidrug-resistance in Mycobacterium tuberculosis by phenotype-and molecular-based assays"},{"key":"2025061108100758000_2025.06.08.25329229v1.40","doi-asserted-by":"crossref","unstructured":"Li M , Oliveira Passos D , Shan Z , Smith SJ , Sun Q , Biswas A , et al. Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants. 2023;9(29):eadg5953.","DOI":"10.1126\/sciadv.adg5953"},{"issue":"7","key":"2025061108100758000_2025.06.08.25329229v1.41","first-page":"997","volume":"15","year":"2014","journal-title":"Dose reduction of efavirenz: an observational study describing cost\u2013effectiveness, pharmacokinetics and pharmacogenetics"},{"issue":"8","key":"2025061108100758000_2025.06.08.25329229v1.42","doi-asserted-by":"crossref","first-page":"e0183080","DOI":"10.1371\/journal.pone.0183080","article-title":"Sub-therapeutic nevirapine concentration during antiretroviral treatment initiation among children living with HIV: Implications for therapeutic drug monitoring","volume":"12","year":"2017","journal-title":"PloS one"},{"issue":"6","key":"2025061108100758000_2025.06.08.25329229v1.43","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/00007691-199712000-00011","article-title":"Stability of rifampin in plasma: consequences for therapeutic monitoring and pharmacokinetic studies","volume":"19","year":"1997","journal-title":"J Therapeutic drug monitoring"},{"key":"2025061108100758000_2025.06.08.25329229v1.44","unstructured":"Subashini R. Oral Delivery of ascorbic acid stabilized rifampicin nanoparticles for enhanced bioavailability of rifampicin: Swamy Vivekanandha College of Pharmacy, Tiruchengode; 2013."},{"key":"2025061108100758000_2025.06.08.25329229v1.45","first-page":"225","article-title":"Acosta EPJJoCB","volume":"945","year":"2014","journal-title":"A sensitive HPLC\u2013MS\/MS method for the determination of dolutegravir in human plasma"},{"key":"2025061108100758000_2025.06.08.25329229v1.46","doi-asserted-by":"crossref","unstructured":"Lamorde M , Fillekes Q , Sigaloff K , Kityo C , Buzibye A , Kayiwa J , et al. Therapeutic drug monitoring of nevirapine in saliva in Uganda using high performance liquid chromatography and a low cost thin-layer chromatography technique. BMC Infect Dis. 2014;14:473.","DOI":"10.1186\/1471-2334-14-473"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.06.08.25329229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:38:00Z","timestamp":1768509480000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.06.08.25329229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":46,"URL":"https:\/\/doi.org\/10.1101\/2025.06.08.25329229","relation":{},"subject":[],"published":{"date-parts":[[2025,6,9]]},"subtype":"preprint"}}